Clinical Trial Detail

NCT ID NCT02574078
Title A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Bristol-Myers Squibb
Indications

non-small cell lung carcinoma

Therapies

nab-paclitaxel

Crizotinib

Bevacizumab + Pemetrexed

Paclitaxel

Docetaxel

Nivolumab

Pemetrexed

Gemcitabine

Erlotinib

Carboplatin

Age Groups: adult

Additional content available in CKB BOOST